A Study of a New PET Scanner in People With Cancer
Quality Improvement Study of a New Generation of Whole Body PET Scanners
1 other identifier
observational
90
1 country
7
Brief Summary
The researchers are doing this study to test the capabilities of a new total-body PET scanner called the Biograph Vision Quadra. The researchers want to learn whether this scanner can produce better PET/CT images and provide more useful imaging information than standard PET/CT scanners.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jun 2026
Typical duration for all trials
7 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 30, 2026
CompletedFirst Submitted
Initial submission to the registry
July 1, 2026
CompletedFirst Posted
Study publicly available on registry
July 8, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2029
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 1, 2029
July 8, 2026
July 1, 2026
2.9 years
July 1, 2026
July 1, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
image quality
Detection of any new/additional lesions on the delayed scan will be recorded using standard clinical interpretation.
3 years
Study Arms (1)
Patients with lung, head and neck, and prostate cancer
The only investigational aspect of this quality improvement protocol is the acquisition of additional PET/CT imaging data (e.g. breath-hold, dynamic, and/or delayed acquisition) in patients who are already scheduled to receive a PET/CT scan as part of standard of care or under an existing clinical trial.
Interventions
new total-body PET scanner, 1 or 2 additional scans with the Biograph Vision Quadra scanner.
Eligibility Criteria
Any MSKCC patients with histologically confirmed cancer, who will be scheduled to receive a planned PET-CT scan at the MSK main campus may be enrolled in this image evaluation and improvement study. Potential patients will be identified by a member of the patient's treatment team at MSKCC, who will introduce the study to them.
You may qualify if:
- Eligibility Criteria for objective #1:
- Patients with histologically-confirmed non-small cell lung carcinoma (NSCLC) with a single or multiple lung nodules.
- Patients who are undergoing a planned PET-CT scan at main campus of MSK.
- Patients must be ≥ 18 years old
- Eligibility Criteria for objective #2:
- Patients with disease within the chest, abdomen or pelvis, who could benefit from visualizing the pharmacokinetics of radiotracer uptake within all disease sites simultaneously.
- Patients with metastatic prostate or head and neck cancer.
- Patients with prostate cancer who are undergoing a 68Ga-PSMA or 18F-FDG scan at the main campus of MSK.
- Patients with head and neck cancer who are undergoing a 18F-FDG scan at the main campus of MSK
- Patients must be ≥ 18 years old
- Eligibility Criteria for objective #3:
- Patients with histologically-confirmed cancer from all three groups (lung cancer, head and neck cancer, prostate cancer).
- Patients who are undergoing an 68Ga-PSMA or 18F-FDG or an \[18F\]-fluormisonidazole PET-CT scan at the main campus of MSK.
- Patients willing to return to the MITS clinc for late imaging session between 2 to 6 hours after the PET radiotracer injection. (In current practice, FDG is imaged between 1 and 1.5 hours post injection, and FMISO is imaged between 2.5 and 3 hours post injection)
- Patients must be ≥ 18 years old
You may not qualify if:
- Patients who suffer from claustrophobia.
- Women who are pregnant or breast-feeding.
- Patients \< 18 years of age
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (7)
Memorial Sloan Kettering Basking Ridge (Consent Only)
Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Monmouth (Consent Only)
Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Bergen (Consent Only )
Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Suffolk-Commack (Consent Only)
Commack, New York, 11725, United States
Memorial Sloan Kettering Westchester (Consent Only)
Harrison, New York, 10604, United States
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Memorial Sloan Kettering Nassau (Consent Only)
Rockville Centre, New York, 11553, United States
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Heiko Schoder, MD
Memorial Sloan Kettering Cancer Center
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 1, 2026
First Posted
July 8, 2026
Study Start
June 30, 2026
Primary Completion (Estimated)
June 1, 2029
Study Completion (Estimated)
June 1, 2029
Last Updated
July 8, 2026
Record last verified: 2026-07
Data Sharing
- IPD Sharing
- Will share
Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.